Paul A. Wagner, Ph.D., Chief Executive Officer, President and Chairperson of the Board

Dr. Wagner founded Forte, has served as President and Chief Executive Officer of Forte since 2018, and has served as a member of Forte’s board of directors since 2017. In 2017, Dr. Wagner was the Head of Corporate Strategy and Development at CANBridge Life Sciences. From 2014 to 2017, Dr. Wagner was the Chief Financial Officer of Pfenex Inc., a biotechnology company. From 2006 to 2014, Dr. Wagner held the positions of Director and Portfolio Manager/Sr. Equity Analyst with Allianz Global Investors, an investment manager where he was responsible for biotechnology and pharmaceutical investments. Prior to that, Dr. Wagner was the Head of Development Licensing at PDL BioPharma, a biopharmaceutical company from 2005 until 2006. Prior to PDL BioPharma, Dr. Wagner held the position of Vice President at Lehman Brothers, a financial services firm, starting in 1999 until 2005. Dr. Wagner received a B.S. from the University of Wisconsin and a Ph.D. in Chemistry from the California Institute of Technology. Dr. Wagner is also a Charted Financial Analyst (CFA) charter holder.

Antony A. Riley, C.P.A, Chief Financial Officer

Mr. Riley has served as Forte’s Chief Financial Officer since March 2020. Prior to joining Forte, Mr. Riley was at Krystal Biotech, Inc., a biotechnology company, from September 2017 to February 2020 where he was the Chief Financial Officer. Previously, Mr. Riley was a founding partner since 2002 of the CFO Network LLC, a consulting firm and was Acting Chief Financial Officer at Avanex Corporation and Corporate Controller at Kosan Biosciences. He also served in numerous capacities at Troy Chemical Corporation from 1997 to 2000. Mr. Riley received a B.Sc. (Honors) from the University of Bristol (England) and an M.B.A. (Honors) from the University of Chicago, Booth School of Business. Mr. Riley is a licensed CPA in the state of California.

Daniel J. Burge, M.D., Chief Medical Officer

Dr. Burge serves as our Chief Medical Officer and heads clinical development at Forte. Dr. Burge has 23 years of experience in the biotechnology and pharmaceutical industry. Prior to joining Forte, Dr. Burge was the Senior Vice President of Clinical Development at Dermira, Inc., a biopharmaceutical company, where he managed a Phase 3 program partnered with UCB that led to the approval of Cimzia for the treatment of psoriasis and a Phase 2 program for the treatment of atopic dermatitis. Prior to Dermira, Dr. Burge worked with Gilead Sciences, a biotechnology company, contributing to the development of novel agents for rheumatic diseases. Dr. Burge was also previously Chief Medical Officer at Trubion Pharmaceuticals, a biopharmaceutical company, Vice President of Clinical Development at Amgen, a biopharmaceutical company, and Vice President of Clinical Development at Immunex, a biopharmaceutical company. Dr. Burge received his MD from Thomas Jefferson University and his BA from Taylor University, Upland, IN.

Henry W. Talbot, Ph.D, Upstream Manufacturing and Quality

Dr. Talbot is the Head of Upstream Manufacturing and Quality for Forte. Dr. Talbot has 35 years of experience in the biotechnology industry, focused on process development, manufacturing, and quality assurance. Prior to Forte, Dr. Talbot served in various roles at Pfenex Inc., a biotechnology company, including as Vice President, Quality and Facilities Operations, from 2015 to 2017 and Vice President, Research & Operations, from 2009 to 2015. Dr. Talbot was also previously a Site Leader at The Dow Chemical Company from 2007 to 2009, a Senior Leader at Dow from 1999 to 2007, a Director at Mycogen Corporation from 1992 to 1999, and had various research roles prior to joining Mycogen. Dr. Talbot received a Ph.D. in microbiology from Oregon State University, an M.S. in microbiology from the University of Missouri and a B.A. in biology from the University of Colorado.